Atopic Dermatitis - The Dermatology Digest

Arcutis Submits Roflumilast Cream 0.05% (Zoryve) sNDA to the FDA for Mild to Moderate AD in Children Aged 2 to 5

December 16, 2024

Organon’s Phil Brown, MD, JD Discusses FDA Nod for Tapinarof Cream 1% in AD

December 16, 2024

From the Editor: ‘Tis the Season for New AD Approvals

December 14, 2024

More Breaking News: U.S. FDA Approves Nemolizumab (Nemluvio, Galderma) for Patients with Moderate to Severe AD

December 13, 2024

Breaking News: Tapinarof Cream 1% (Vtama, Organon) Approved in AD

December 13, 2024

CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate to Severe AD and PN in the European Union

December 13, 2024

Advertisement

Latest Issue

Latest Supplements

Advertisement

Digital Edition Archive

Advertisement